Immunosuppression (I-S) may be defined as (a) a state in which the capacity of an animal or person to form antibody or to mount a cell-mediated immunological reaction in response to an antigenic stimulus is reduced; or (b) the process by which this state is produced. It will be seen that this definition includes some effects which are commonly described as anti-inflammatory. This seems unobjectionable to me and, in our present state of knowledge, unavoidable. It might be more logical to use instead the term immunodepression, and reserve immunosuppression for the condition in which immunological responsiveness-is completely abolished, but the definition I have given is in accordance with current usage.
If the diminished responsiveness is restricted to a single antigen, or to a small group of related antigens, it may be described as specific; otherwise it is non-specific. These terms are convenient but must be used with caution because a high degree of specific immunosuppression may be superimposed on a lesser degree of non-specific suppression, and conversely in non-specific suppression some types of reaction, or the reaction to some particular types of antigen, may be preferentially suppressed.
It has been known for a long time that wholebody X-irradiation may decrease the capacity of an animal to form antibody to bacteria and heterologous erythrocytes (Hektoen 1915 , 1918 , 1920 , Murphy & Sturm 1925 , Craddock & Lawrence 1948 and also, at least in the rat, diminishes the reaction to tumour heterografts (Murphy 1914 (Murphy , 1926 . The clinical need for homografts, and the discovery of the immunological nature of homograft rejection (Gibson & Medawar 1943 , Medawar 1944 interest in I-S and a few years later Dempster et al. (1950) reported that the survival of skin homografts in rabbits was increased by irradiation of the prospective recipient prior to grafting. This was followed by the discovery of other agents which cause non-specific I-S, and by the demonstration that immunological reactivity may be impaired in children suffering from congenital hypogammaglobulinwemia (Good 1954 , Good & Varco 1955a , and in pregnant animals (Heslop et al. 1954) . Meanwhile the remarkable insight of Owen (1945) into the significance of chimerism in dizygotic cattle twins, the inspired prediction of Bumet & Fenner (1949) and the brilliant experimental work of Billingham et al. (1953) had led to the recognition of one form of specific immunosuppression, both as a laboratory phenomenon and as an experiment of nature.
Immunosuppression, both non-specific and specific, has since been the subject of intense study, partly because of its fundamental scientific interest, and partly because of its clinical importance in relation to organ transplantation and the treatment of autoimmune disease.
Non-specific Immunosuppression
The causes of non-specific I-S are legion. The inventory given in Table 1 makes no pretence at completeness, nor is it put forward as a rational classification, which, as Medawar (1968) has pointed out, can be founded only on a much more detailed understanding of the natural history of the immunological response than we at present possess. Some of the possible mechanisms by which these agents may cause I-S are listed in Table 2 . It has been suggested by Brent & Medawar (1966 that neither irradiation nor the cytotoxic and antiproliferative drugs affect any cellular activity peculiar to or distinctive of the immunological process as such; in their opinion these agents cause immunosuppression simply by 'preventing the multiplicative expansion of a small reactive lymphocyte population into the relatively large population of reactive cells characteristic of the sensitized state' (Medawar 1968 ). This interpretation is almost certainly an over-simplification; thus Medawar himself has pointed out that it may not hold good for immunological reactions mediated through humoral antibodies, and Gallily & Feldman (1967) 
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Antibody synthesis by AFC Effector mechanisms: Complement + free antibody; sensitized cells ASC, antigen-sensitive cell AFCP. antibody-forming cell precursor AFC, antibody-forming cell have shown that X-irradiation in appropriate dosage may interfere with the capacity of macrophages to process antigen to an 'immunogenic' state. It is clear, however, that these agents do exert profound effects on dividing cells of all kinds, and this is the reason for some of the complications of immunosuppressive therapy which we shall presently consider. I am not qualified to discuss how these effects are produced; fortunately, however, what is known about this has been lucidly expounded in excellent reviews by Berenbaum (1965 Berenbaum ( , 1967a and others.
I am equally unqualified to discuss the mode of action of the corticosteroids, and will content myself with the comment that the reversal of acute rejection of a kidney homograft by very large doses of steroids, and the effect of chronic administration of smaller doses, may well be mediated in fundamentally different ways.
I feel less inhibited about discussing the mode of action of antilymphocytic serum (ALS), if only for the reason that I have been interested in the immunosuppressive properties of this material for twenty years.
It has been pointed out by several groups of investigators (for review see Woodruff 1969) that, contrary to what was at first expected, the level of immunosuppression is not entirely dependent on the degree of lymphoid depletion which is produced. It would seem, therefore, that ALS does not produce its effects simply by indiscriminate killing of lymphocytes and their precursors. On the other hand preparations which are devoid of cytotoxic activity, whether of whole antibody, antibody fragments or antibody modified by treatment with acid, do not appear to be immunosuppressive (Anderson et al. 1967 (Anderson et al. , 1968 ). These findings can be reconciled by postulating, as Taub (1969) and others have done, that one of the main ways in which ALS causes immunosuppression is by bringing about selective depletion of the pool of long-lived recirculating lymphocytes.
Other hypotheses are (a) that lymphocytes become coated with antibody and in consequence are rendered immunologically ineffective, and (b) that ALS causes a generalized 'sterile activation' of lymphoid cells. The demonstration that the uptake of uridine and thymidine by lymphocytes in vitro is increased by exposure to ALS or antilymphocytic globulin (ALG) seemed at first to provide support for the last of these hypotheses, but two facts tell decisively against it: (1) F(ab'), and acid-treated material prepared from ALG, which show little immunosuppressive activity, cause increased uptake of uridine and thymidine by lymphocytes in vitro comparable to that produced by ALG.
(2) Stimulation of lymphocytes by ALG is inhibited by complement.
Specific Immunosuppression
Specific I-S may be induced by administration of antigen (in which case it is also termed specific immunological tolerance or immunological paralysis) or antibody. Various factors determine whether or not injection of antigen will result in tolerance; these include the physical form of the antigen, the dose and route of administration, the age and species of the recipient, and whether or not agents which can cause non-specific I-S are also employed. Much interest centres on the possibility of making normal adults tolerant of transplantation antigens. Attempts to achieve this by injecting solubilized antigen preparations without other treatment have so far proved disappointing; on the other hand introduction of antigen, whether in the form of a suspension of viable cells, a tissue extract or even a solid graft, combined with irradiation (see Woodruff 1965), administration of cytotoxic drugs (see e.g. Schwartz 1965 , Halasz et al. 1966 , Floersheim 1967 , and administration of ALS alone (Lance & Medawar 1969) or in combination with thymectomy (Monaco 1969 ), has achieved considerable success in experimental animals.
Specific I-S induced by antibody was first recognized in the context of tumour transplantation by Kaliss (1957) who gave it the somewhat unfortunate name of enhancement, but the phenomenon is of much wider immunological significance (see Wigzell 1969) .
There has been much discussion about the respective roles of afferent, efferent and central inhibition (Medawar 1956 ) in enhancement (see M6ller 1963) , and also of the role played by enhancement in facilitating the survival of homotransplants of normal tissues and organs. It may well be, as Medawar (1968) has suggested, that enhancement is too often summoned to account for the anomalously long survival of homografts when other explanations have failed; on the other hand it is important to remember that suppression of antibody formation may in some circumstances be disadvantageous in recipients of organ transplants.
An important therapeutic application of I-S by administration of antibody, which we owe to Clarke (1968) and his colleagues, is the prevention of rhesus iso-immunization in Rh-negative women who have had an Rh-positive (but ABO compatible) baby by anti-D plasma or y-globulin.
Immunosuppression in Clinical Practice
The present indications for immunosuppressive therapy fall under two main headings: (I) Disease in which the mortality and/or morbidity are due, or partly due, to autoimmunity or some other form of immunological reaction. (2) Homotransplantation.
In autoimmune disease the therapeutic objective is to abolish or control a reaction which is already established, whereas in transplantation prophylactic treatment may be instituted before the reaction has begun. Despite this, considerable benefit can often be obtained with doses of I-S agents which are almost homoeopathic in comparison with those required in transplant recipients. The only other comment I wish to make on this subject is to -echo Berenbaum's (1967c) kidney from his father, and this is far from being a world record. The mean survival rates were, however, distinctly less for these earlier cases, especially in respect of cadaver transplant recipients where the one-year survival was only 27%. The main reason for the difference is that a patient can now be maintained by hemodialysis if, as often happens with cadaver transplants, adequate function is not established for a week or two. Since we have as yet no comparable means of maintaining patients whose livers or hearts are not functioning, and since liver and heart transplants obviously cannot be obtained from living volunteers, it is clear that transplantation of these organs is subject to the same kind of limitation as kidney transplantation was before regular dialysis was possible; the degree of limitation is, however, even greater, because a previously healthy person can live for about ten days after the sudden loss of both kidneys, which is much longer than one can live without a liver and a fortiori longer than one can live without a heart. The point needs stressing because many people who are new to 414 Proc. roy. Soc. Med. Volume 62 April1969 transplantation talk as if the only bar to successful heart and liver transplantation were the immunological one, but this is not so. I know of no evidence which suggests that the immunological barrier is greater for cardiac than for renal transplants, and it looks as if liver transplants may be particularly favourable from this point of view (Calne et al. 1969 ).
The first immunosuppressive agent to be used clinically in transplant recipients, apart from very small doses of steroids, was whole-body irradiation, but this is now obsolete. The agents now used routinely are azathioprine, an antimetabolite closely related to 6-mercaptopurine which was introduced into transplantation by Calne (1960) , and prednisone (or prednisolone). Actinomycin D is often used for the treatment of threatened rejection, and in some clinics local irradiation of the transplant is also used for this purpose. IgG prepared from horse-anti-human ALS is also being used in several clinics in conjunction with other agents, both for routine immunosuppression and for the treatment of rejection.
Complications
Treatment with immunosuppressive agents entails the risk of complications, some of which may be extremely serious or even fatal. These complications include infection, wasting, hemorrhage associated with thrombocytopenia, neoplastic disease and various special complications caused by steroids and ALS.
Infection: Infection due to bacteria and fungi is a serious and often fatal complication of immunosuppressive therapy; it accounted, for example, for 48 out of 60 deaths in a series of transplant recipients reported by Hill et al. (1967) , and for 8 out of 20 deaths among 35 patients who received renal transplants in Edinburgh. Viral infection so far does not seem to have been a major clinical problem, though fatal viral infections of various kinds have been reported in dogs (Abaza et al. 1966) , monkeys (Balner et al. 1968 ) and mice (Hirsch & Murphy 1968 ) treated with ALS.
The danger of infection from outside can be reduced by isolating a patient when he is most at risk, and in the Nuffield Transplantation Surgery Unit we are investigating what can be achieved in this direction when precautions against crossinfection are pushed to extremes ).
There remains the risk of infection by normally harmless organisms carried by the patient on his skin and mucous membranes; the best defence here is ceaseless vigilance and prompt specific treatment.
It is our normal practice to send patients home when they are discharged from the Nuffield Unit, and this is satisfactory provided that (a) home conditions are adequate, and (b) the patient, his relatives and his family doctor realize that he should be referred back if he develops any infection, however innocuous it may appear. The disastrous consequences which may occur if an originally mild infection is neglected are illustrated by a patient of ours who developed a sore throat while at home five months after he had received a kidney transplant. Medical advice was not sought for three days, by which time he was in a severely collapsed state with pneumococcal septicmmia. Despite vigorous antibiotic treatment and reduction of his immunosuppressive therapy to the point where transplant rejection developed, he died of a lung abscess and empyema. Prompt treatment, on the other hand, may succeed even when the infection is of a particularly unfavourable kind. This is illustrated by another patient who was readmitted fourteen months after renal transplantation with backache and fever. This was at first attributed to osteoporosis and lobar pneumonia, but when signs of meningitis appeared a lumbar puncture was done and Cryptococcus neoformans was isolated from the CSF. This responded to treatment with amphotericin B, and although the patient's creatinine clearance fell sharply it has now returned to normal.
While infection is always potentially dangerous, another case of ours raises the bizarre possibility that, by contributing significantly to the patient's immunosuppression, it may actually be beneficial. Thispatient, who is very fit and has excellent renal function three years after receiving a cadaveric transplant, has a persisting Ps. pyocyanea infection of the urinary tract. This has been treated on three occasions with polymyxin and each time there has been a sharp but temporary decline in renal function. At the time this was attributed to the nephrotoxic effect of polymyxin, but the observation of Stone et al. (1967) that a substance having immunosuppressive properties can be extracted from certain strains of pseudomonas has made us have second thoughts about this.
Muscular wasting: Gross muscular wasting develops occasionally in patients on azathioprine. We have been disposed to ascribe this to general interference with protein synthesis, but it may be akin to the wasting which follows experimental lymphoid depletion produced in a variety of ways (see Denman & Frenkel 1967) .
Thrombocytopenia: A moderate degree of thrombocytopenia is often seen in patients on cytotoxic immunosuppressive drugs, but usually responds 22 Section of Clinical Immunology and Allergy 415 well to temporary withdrawal of the drug. Severe thrombocytopenia occurred in the one patient we have treated by whole-body irradiation, and has occurred more recently in several patients who have received ALG.
Neoplastic disease: One of our patients died from a reticulum cell sarcoma twenty-five months after renal transplantation; 4 other cases of malignant lymphomas in renal transplant cases have now been reported (Penn et al. 1969) , and I have recently heard of 2 more (Doak 1968, personal communication). All these patients had received azathioprine and prednisone. Some, but not all, had received ALG; our own patient is included among those who had received ALG but there is radiological evidence that the tumour was present before this treatment was begun. That at least 7 such tumours should develop among some 1,700 kidney transplant recipients is highly significant, and it seems likely that prolonged immunosuppression was the common wtiological factor.
There are several reasons why it would not be altogether surprising if patients subjected to prolonged immunosuppressive therapy showed a high incidence of tumours of various kinds. In the first place many immunosuppressive agents are mutagenic and some have been shown to be frankly carcinogenic. Secondly, it has been shown experimentally that viral oncogenesis may be potentiated by various immunosuppressive agents including ALS (Allison & Law 1968 , Vandeputte 1969 . Thirdly, I-S would be expected to facilitate the growth of those tumours that possess tumour-specific antigens. Many animal tumours, in particular those induced by chemical carcinogens or of viral origin, do possess such antigens, and it would be astonishing if the same were not true of at least some human tumours.
Yet in fact, until the recent crop of malignant lymphomas, the incidence of cancer in renal transplant recipients has not been sufficient to attract attention except when the tumour had obviously been transmitted with the graft from the donor (Wilson et al. 1968 ), presumably in the form of minute, unseen metastatic deposits, or viable tumour cells in the lumen of the vessels of the transplant. One of our patients, indeed, who might well have been expected to have had residual cancer when immunosuppression was started three years ago, has surprised us by remaining clinically free of tumour ever since. This man had had a left nephrectomy for hypernephroma in 1962, and in 1965 he presented with a huge hypernephroma of his remaining kidney. He was given a cadaveric transplant and a few days later his right kidney was removed. At operation tumour was found to extend along the renal vein as far as the vena cava.
Special complications due to corticosteroids: These include a cushingoid appearance, hypertension, osteoporosis, and ulceration of the stomach and duodenum. The first three have occurred frequently in our patients and seem at present unavoidable if large doses of prednisone are given for a -long time. Gastroduodenal ulceration has not been a problem except in one case, possibly because we have insisted on all patients on prednisone taking antacids.
Special complications due to ALS and derivatives: Thrombocytopenia has already been mentioned. It seems to be much more of a problem in some patients than others given the same material. Attempts to absorb out anti-platelet activity have not so far been very successful. Another serious complication is the appearance of a painful inflammatory swelling at the site of injection. This can be so severe that after a few injections no more can be given. The nature of the reaction and possible ways of avoiding it are under investigation.
Future Developments
There is much to be learned about how to make the best use of immunosuppressive agents which are already available. It is urgently necessary to find some way of reducing the dose of steroids without loss of immunosuppressive effect. This may well be achieved by giving antilymphocytic globulin (ALG) provided in turn that a method can be found of giving larger doses than those being used at present and at the same time reducing the incidence and severity of complications. One procedure which we are investigating is administration of ALG by continuous intravenous infusion. The main dangers which have to be circumvented would seem to be (a) acute anaphylactic shock and (b) renal damage due to reaction of the ALG with antigenic determinants in constituents of the kidney or deposition of complexes of ALG and antibody formed by the treated patient which reacts with it.
Looking further ahead one would hope to see the development of clinically applicable methods of inducing specific tolerance of donor antigens in the period before or immediately after organ transplantation. If this were achieved it should be possible to stop administration of immunosuppressive agents after a short time, and thus avoid many of the complications which arise from the present practice of continuing some form of immunosuppressive therapy more or less indefinitely. If you ask whether this practice is really necessary I can only say that one patient in whom we discontinued azathioprine administration five years after he had received a kidney from his 416 Proc. roy. Soc. Med. Volume 62 April 1969 24 father had a moderately severe rejection crisis three weeks later. This seems all the more surprising in that there appeared to be a very high degree of compatibility and for three years prior to its total withdrawal he had received only 25 mg azathioprine per week. Fortunately renal function was fully restored by prompt treatment but the patient is still receiving azathioprine more than a year later.
If the immunological barrier to homotransplantation were completely removed it would not, for reasons I have already given, solve all the problems of organ transplantation. It would, however, greatly improve the outlook for patients with severe irreversible renal failure. It would also have dramatic consequences in plastic surgery, where transplantation of cadaver skin, instead of being merely a temporary expedient, would become the definitive treatment of extensive skin loss due to burns and other causes.
Conclusion
It is obvious that modern medicine owes much to immunology. It is equally true that immunology, as a scientific discipline, owes much to medicine, for its inspiration, for the raw material on which so many fruitful investigations have been based and for the contributions which clinicians have made to fundamental immunological discoveries. I was tempted indeed to choose as the subject for this address, 'Immunology's Debt to Medicine', but I decided otherwise, partly because immunosuppression is of such current interest, but also because this subject so well illustrates the general thesis which I have just propounded.
We seem to be on the threshold of an era of unparalleled advances, which will see the solution of the clinical problems of preventing rejection of homografts and possibly also heterografts, and of controlling autoimmune disease, and the growth of a much deeper understanding of the complex train of events which follows immunological stimulation. It seems certain that the study of immunosuppression will play a major part in these exciting developments.
